Re: I-SPY2
When asked by analysts at previous conferences how the Marianne trial was progressing, Roche's frequently answered that, because it was a blinded trial, they really didn't had received any information from investigators.
That response was probably 100% correct as far as the Marianne trial was concerned. However, it now occurred to me that Roche is closely involved as a member of that QuantumLeap Healthcare Collaborative, which is keeping very close track how the participants respond to their specific treatments in order to plot failure/success charts on a real-time basis.
So Roche today should have a pretty good insight as to how well the Kadcyla/Pertuzumab arm is doing in this investigation. I believe success is measured by 100% reduction in tumor burden which would circumvent the planned for follow-up surgery.